Short Communication

Sam-Pointed Domain Containing Ets Transcription Factor in Luminal Breast Cancer Pathogenesis

Ashwani K. Sood,1 Jianmin Wang,2 Paulette Mhawech-Fauceglia,3 Bagirathan Jana,4 Ping Liang,2,5 and Joseph Geradts3

Departments of 1Immunology, 2Bioinformatics Resource, 3Pathology, 4Medicine, and 5Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York

Abstract

We previously described frequent overexpression of Sam-pointed domain containing Ets transcription factor (SPDEF), also known as PDEF, in human breast cancer, and suggested a role for this transcription factor in breast tumor progression. To seek evidence in support of this hypothesis, the MCF-12A breast epithelial cell line was transfected with an SPDEF expression plasmid or with control vector plasmid and the transfected cells tested for their tumorigenic growth in vivo. The data showed that SPDEF expression in MCF-12A cells induced accelerated tumor growth in severe combined immune deficient mice compared with vector-transfected MCF-12A cells. Furthermore, Gene Expression Omnibus and Oncomine databases were mined to determine any correlation between SPDEF expression levels and clinical outcome. High SPDEF expression correlated with poor overall survival of patients with estrogen receptor+ breast cancer, in three independent data sets. In contrast, little correlation was observed between SPDEF expression and cancer relapse or remote metastases. SPDEF expression was further found to be restricted to tumors arising in the luminal epithelial lineage including estrogen receptor+ luminal subtype breast tumors, Her2/neu-positive tumors, and apocrine carcinomas. In contrast, little SPDEF expression was found in the basal subtype of breast tumors. Based on these results, we hypothesize that SPDEF has a function in the specification of the progenitor cells of the luminal epithelial lineage that become targets of oncogenesis in luminal breast cancer.


Introduction

Changes in the activities of specific transcription factors are known to specify cell fates along alternate lineages in the hematopoietic developmental programs (5). For example, GATA-1 and PU.1 transcription factors control differentiation of the common precursors along erythroid versus myeloid lineage, and GATA-3 and T-bet transcription factors specify restricted differentiation to TH2 versus TH1 lineage, respectively (reviewed in ref. 5). Moreover, aberrant activation and expression of these and other transcription factors is a significant contributor to the development of leukemia in man (5). These observations highlight the fine balance in transcription factor regulation that separates normal from neoplastic development and emphasize the importance of studying the role of specific transcription factors in normal developmental processes and in cancer. Despite such importance, our understanding of the role of specific transcription factors in normal mammary gland development remains rudimentary. Moreover, the dynamics of activation and/or inactivation of specific transcription factors in the genesis of luminal versus basal breast cancer subtypes remains to be elucidated.

Sam-pointed domain containing Ets transcription factor (SPDEF), such as PU.1 described above, belongs to the Ets family of transcription factors that regulate many of the developmental processes including cell lineage specification, proliferation, differentiation, angiogenesis, and apoptosis, and are instrumental in the oncogenesis caused by their aberrant activation and expression.

Received 1/16/09; revised 3/24/09; accepted 4/8/09; published online 6/8/09.
Grant support: Grants CA 86164 from National Cancer Institute, BC045095 from the Department of Defense and 862-2333 from Roswell Park Alliance Foundation. The institutional facilities used in this research were supported by Roswell Park Cancer Center Support grant P50CA16056.
Note: Current address for B. Jana: Department of Hematology and Oncology, Florida Hospital, 7975 Lake Underhill Road, Suite 130, Orlando, FL 32822. Current address for J. Geradts: Department of Pathology, Duke University Medical Center, Durham, NC.
Requests for reprints: Ashwani Sood, Department of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 716-845-2395; Fax: 716-845-8968. E-mail: ashwani.sood@roswellpark.org
Copyright © 2009 American Association for Cancer Research.
doi:10.1158/1055-9965.EPI-09-0035


Downloaded from cebp.aacrjournals.org on April 20, 2017. © 2009 American Association for Cancer Research.
(reviewed in refs. 6, 7). We previously reported a detailed study of SPDEF protein expression during breast tumor progression and showed that individual samples vary greatly with regard to the intensity of staining and the percentage of positively staining cells. Nevertheless, increase in the expression of SPDEF protein was frequently observed in progression from benign breast tissue to carcinoma and this was further confirmed in the large majority of matched samples of benign breast and tumor tissues from same patients (8). Such breast tumor–associated expression of SPDEF raised the potential for its role in mammary gland development and in the pathogenesis of breast cancer. Moreover, the potential of SPDEF in lineage specification and/or in luminal versus basal breast cancer development seemed intriguing. In this article, data are presented that support a role for SPDEF in the pathogenesis of luminal breast cancer.

Materials and Methods

Cell Lines and Mice. The MCF-12A human mammary epithelial cell line was obtained from American Type Culture Collection and cultured in Supplier’s suggested medium in 5% CO2 at 37°C. CB17/Icr female severe combined immunodeficient–/– mice were purchased from Taconic Farms.

Generation of SPDEF-Expressing MCF-12A Cells and Testing of Tumorigenicity in Severe Combined Immunodeficient Mice. The full-length coding region of SPDEF was amplified from normal human prostate RNA by reverse transcription-PCR. The SPDEF-specific primers used in the amplification were as follows: 5′-ATGG GCC AGC CCG GGT C-3′ (forward) and 5′-TCA GAT GGG GAT CCC GGT C-3′ (reverse), respectively. The PCR product was cloned into the TA cloning site of pcDNA3.1/v5-His TOPO mammalian expression vector (Invitrogen). The orientation and sequence of the cloned cDNA was confirmed by DNA sequencing. Ten micrograms of the SPDEF expression plasmid were transfected into the MCF-12A cell line by using Lipofectamine 2000 (Invitrogen) transfection reagent and by using the manufacturer’s suggested procedure. Stable transfectants were obtained by selection with G418 sulfate. As control, MCF-12A cells were also transfected with the vector plasmid and stable transfectants selected similarly. SPDEF expression in transfectants was tested by Western blotting, using an anti-SPDEF antibody described previously (8). As shown in Fig. 1A, a specific band at 46 kDa was found in the SPDEF plasmid–transfected cells but not in the vector-transfected cells. The tumorigenicity of SPDEF-expressing cells and SPDEF-lacking MCF-12A cells were transfected with control vector plasmid and stable transfectants isolated by selection with G418. Expression of SPDEF protein in the transfected cells was tested by Western blotting, using an anti-SPDEF antibody described previously (8). As shown in Fig. 1A, a specific band at 46 kDa was found in the SPDEF plasmid–transfected cells but not in the vector-transfected cells. The tumorigenicity of SPDEF-expressing cells and SPDEF-lacking vector-transfected cells was then tested in severe combined immunodeficient mice each and tumor growth monitored. The tumor volume at various time points is the average for three mice from each group.

Results

Transfection of SPDEF into the MCF-12A Breast Epithelial Cell Line Enhances Its Tumorigenic Growth in Immunodeficient Mice. SPDEF expression plasmid was generated by amplifying the coding region of SPDEF by reverse transcription-PCR, followed by its insertion into pcDNA3.1/v5-His TOPO mammalian expression vector (see Materials and Methods). This expression plasmid was transfected into MCF-12A cells. Also, MCF12A cells were transfected with control vector plasmid and stable transfectants isolated by selection with G418. Expression of SPDEF protein in the transfected cells was tested by Western blotting, using an anti-SPDEF antibody described previously (8). As shown in Fig. 1A, a specific band at 46 kDa was found in the SPDEF plasmid–transfected cells but not in the vector-transfected cells. The tumorigenicity of SPDEF-expressing cells and SPDEF-lacking vector-transfected cells was then tested in severe combined immunodeficient mice. As shown in Fig. 1B, SPDEF-transfected MCF-12A cells showed faster growth kinetics i.e., about 12 days in advance of the vector-transfected MCF-12A cells.

Higher SPDEF Expression Correlates with Poor Overall Survival for Breast Cancer Patients with Estrogen Receptor+ Tumors. To seek further evidence for a role of SPDEF in breast cancer progression, we searched the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) and Oncomine databases (9) that contain the gene expression profiling and clinical outcome data from several previously published studies (10-15) and looked for any correlation between SPDEF expression levels and clinical outcome. Eleven data sets had disease-specific survival information available and six of those also contained information on SPDEF expression. According
to the clinical data, the six data sets could be classified into three categories: overall survival (two data sets), relapse/metastases-free survival (three data sets), and combination of the two (one data set). Due to adequate numbers of patients with estrogen receptor (ER)+ breast tumors, only those were included in this analysis. The results show that in three independent data sets (10-12), higher SPDEF expression was associated with poor overall survival for patients (Fig. 2A-C). A similar correlation, however, was not found between higher SPDEF expression and relapse or metastases (Fig. 2D-F). The significant correlation between high SPDEF expression and poor overall survival for patients in three separate data sets, nonetheless, provides an important evidence for a role for SPDEF in breast cancer progression.

**SPDEF Expression is Primarily Restricted to Breast Tumors Arising from Luminal Epithelial Lineage.** To obtain additional insights into the expression characteristics of SPDEF in different subtypes of breast cancer, SPDEF expression data were extracted from the gene expression profiling data sets from Minn et al. (14) and Farmer et al. (16). As shown in Fig. 3A, SPDEF was not expressed in any of the 16 tumors of basal subtype. In contrast, 20 of 27 (74%) of luminal tumors, 6 of 6 (100%) of apocrine tumors, and 21 of 23 (91%) Her2/neu-positive tumors expressed SPDEF. These results show restriction of SPDEF expression to tumors arising from the luminal epithelial lineage.

**Discussion**

The role of SPDEF in breast cancer has been a subject of controversy (17, 18). Specifically, transfection of MDA-MB231 and other malignant breast tumor cell lines including MDA-MB157, BT-549, and MDA-MB436 with SPDEF was reported to reduce their growth, motility, and invasiveness in vitro (17). However, in view of the data shown in Fig. 3A, a concern with transfecting these tumor cell lines with SPDEF is that they are of basal origin (19-21), wherein SPDEF is not expressed naturally and may lack a function, so that transfecting SPDEF into the basal tumor cell lines may not yield a physiologic outcome. Moreover, further increase in the malignancy of these already malignant cell lines may not be feasible, although SPDEF has a

---

**Figure 2.** Survival analysis with SPDEF expression in patients with ER-positive breast cancer. Six data sets with survival data and SPDEF expression data were studied. For each data set, the low 25% quartile of SPDEF-expressing samples was categorized as low-expression samples and the high 25% quartile as high-expression samples. Comparison of these low and high expression cohorts from the data sets A (of Chin et al.; ref. 10) and B (of Miller et al.; ref. 11) showed a significantly poor overall survival for the SPDEF high-expression cohort. Also, in the data set C of Ivshina et al. (12) that includes mixed clinical outcome data on overall survival and metastases-free survival, a significant difference was observed between low and high SPDEF expression cohorts. The log-rank test P values are also shown in the figure. In contrast, no significant difference was observed between low and high SPDEF expression cohorts with respect to relapse-free or metastases-free survival of patients in the data sets D (of Wang et al.; ref. 13), E (of Minn et al.; ref. 14), and F (by Sotiriou et al.; ref. 15). Cox proportional-hazard regression analysis, which treats SPDEF expression as a continuous dependent variable, was also done and similar significance levels were obtained for those six data sets.
role in tumor progression. Similar paradoxical results were obtained when ER, another luminal lineage–associated transcription factor, was transfected into the MDA-MB231 basal tumor cell line, and behaved as an apparent tumor suppressor (22).

It seemed more appropriate to use nontransformed or low malignancy breast epithelial cell lines to discern the role of SPDEF in breast tumor progression. Indeed, when SPDEF was transfected into the nontransformed MCF-10A basal tumor cell line, and behaved as an apparent tumor suppressor (22).

The data in Fig. 2 show a significant correlation between high SPDEF expression and poor overall survival for patients with ER+ breast tumors, in three independent data sets. These findings in conjunction with restricted expression of SPDEF to luminal breast tumors (Fig. 3A) show an important role for SPDEF in the pathogenesis of luminal breast cancer, which comprises >80% of the newly diagnosed breast tumors.

Because of their dominant role in cell fate specification and differentiation, function of individual transcription factors in mammary gland development has been the subject of recent inquiries. Specifically, work on GATA-3 transcription factor is noteworthy as it shows a crucial role for this transcription factor in luminal lineage specification and differentiation (23). Similarly, Elf-5 transcription factor was found necessary for lobuloalveolar development during pregnancy (24). Based on the lack of SPDEF expression in basal tumors (Fig. 3A), in basal tumor cell lines including MDA-MB231, MDA-MB157, BT-549, and MDA-MB436 (17) and in nontransformed basal cell lines MCF-10A (18) and MCF-12A, SPDEF function also seems to be restricted to the luminal epithelial cell lineage and in the pathogenesis of luminal breast cancer. The data in Fig. 2 support this notion since high SPDEF expression in ER+ luminal breast tumors was found to be associated with poor overall survival of patients. Additionally, high SPDEF expression was reported in mammary tumors arising in the two transgenic mouse lines including the rat neu and the polyoma virus-middle T antigen transgenic lines (25). Mammary tumors from these mice are of luminal origin (26) and, interestingly, seem to arise from immature luminal precursors because they lack the expression of ER and FoxA1 (26), two of the molecular markers of mature luminal epithelial cells. This suggests that rat neu and polyoma virus-middle T antigen oncogenes preferentially target the SPDEF-expressing immature progenitors to produce aggressive luminal mammary tumors. Our previous observation with human breast tumors also supports this idea because frequent elevated expression of SPDEF was observed in Her2/neu-overexpressing breast tumors (8). On the basis of these observations, we propose a working model of SPDEF function in the specification of progenitor cells of the luminal epithelial lineage (Fig. 3B), which are apparently targeted by oncogenes to initiate breast cancer. Additionally, in tumors initiated through hormone receptor signaling, aberrant overexpression of SPDEF may occur and promote tumor de-differentiation and progression.

### Figure 3

**A.** SPDEF expression in different subtypes of breast cancer. As shown, SPDEF was not expressed in any of the 16 tumors of basal subtype. In contrast, 20 of 27 (74%) of ER-positive/Her2-negative tumors, 6 of 6 (100%) of apocrine tumors, and 21 of 23 (91%) Her2-positive tumors expressed SPDEF. A sample was considered SPDEF-positive if a majority of the probe sets were scored “present” for SPDEF. The error for the proportion is computed with assumption of binomial distribution.  

**B.** A working model of SPDEF function in normal and neoplastic development in the mammary gland. SPDEF expression is depicted to occur in luminal progenitor cells that are targeted by rat neu, polyoma virus-middle T antigen, and possibly other oncogenes. Additionally, aberrant SPDEF expression may occur in hormone receptor–positive tumors to promote their de-differentiation and progression.

---

7 Our unpublished data.

8 M. Aneja and A.K. Sood, our unpublished data.
Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Margot Ip and Dr. Scott Abrams for critical reading of this manuscript and for helpful suggestions.

References

Sam-Pointed Domain Containing Ets Transcription Factor in Luminal Breast Cancer Pathogenesis
